Researchers were able to closely study a Lassa fever patient’s immune response over time after he was evacuated to the US for treatment. An experimental drug, favipiravir, was used in treating the US patient and an additional patient infected with Lassa virus in Germany. The drug appeared to have few serious side effects, but its efficacy is unknown. Individual patient reports cannot be generalized to broader population, but findings suggest promising areas for future research.